Objective: To determine the safety and efficacy of silodosin in the management of acute urinary retention (AUR) related to benign prostatic hyperplasia (BPH).
Methods: From January 2011 to May 2012, 60 men over 50 years of age with AUR were equally randomized to either silodosin 8 mg once daily or placebo for 3 days followed by trial without catheter (TWOC). If the patient re-experienced urinary retention or if postvoid residual urine volume was >150 mL, he was re-catheterized and considered to have a failed TWOC. All patients with a successful TWOC on day 3 were started on silodosin regardless of which arm they had belonged initially. Uroflowmetry, postvoid residual volume and International Prostate Symptom Score (IPSS) were noted at TWOC and after 2 weeks.
Results: Baseline patient demographics and clinical characteristics were similar in both groups (P >.1). The success rate of TWOC was 76.7% in the silodosin group and 36.7% in the placebo group (P = .002). On multivariate analysis, patients in silodosin group had lesser odds of having a failure (0.13) when compared to those not given treatment (P = .008). Among the clinical parameters, a retention volume more than 800 mL (P = .038) and an IPSS score more than 25 (P = .042) had significantly greater odds of failure. There were no adverse effects related to the use of silodosin.
Conclusion: Silodosin significantly increases the chances of successful TWOC after AUR.
Written by:
Kumar S, Tiwari DP, Ganesamoni R, Singh SK Are you the author?
Department of Urology, Postgraduate Institute of Medical Education and Research, Chandigarh, India; and the Department of Urology, Muljibhai Patel Urological Hospital, Nadiad, India. Electronic address:
Reference: Urology. 2013 Apr 3. (Epub ahead of print)
doi: 10.1016/j.urology.2013.02.020
PubMed Abstract
PMID: 23561712
